b'LabPMM Assay GuidelinesMyAML is a targeted gene panel that analyzes the coding and non-coding exons of nearly 200 genes, as well as theThe MyMRD is a NGS-based panel that assesses variants in hotspots from 23 genes that commonly drive myeloid breakpoint hotspots within 36 genes. MyAML combines long read chemistry and deep sequencing with an optimized andmalignancies, including AML, MPN and MDS. It can detect SNVs, indels, and translocations to the genomic basepair, validated custom bioinformatics pipeline, MyInformatics, to specifically examine genomic variants in AML patients .offering unparalleled precision and detection of low level mutations in patients. The MyMRD assay detects at least one driver mutation in 90%-95% of all AMLs.Consider testing with MyMRD as an entry Consider testing with MyAML as an entry pointpoint into clinical trials or to optimize into clinical trials or to optimize treatment treatment and monitor tumor-specificNPM1 markers Patient with suspected orPatient with suspected orB- and T-cell FLT3 or LeukoStratCDx FLT3 Mutation Assay confirmed AML diagnosis confirmed hematologicalclonality testing malignancy accordingto disorderOur FLT3 ITD and NPM1 MRD testsFollow-up with MRD assays unique for biomarkersFollow-up with MRD assays unique for are amplicon-based NGS assays,identified in each patient, such as FLT3 ITD MRD,biomarkers identified in each patient, such as with a limit of detection of 5x10 -5 NPM1 MRD and MyMRDFLT3 ITD MRD and NPM1 MRD MyAML and MyMRD are CLIA validated assays. MyMRD is a CLIA validated assay.54 LabPMM Services Catalog 2021|55'